Back

Initiation of sacubitril/valsartan in patients with renal impairment early after acute decompensated heart failure in the TRANSITION study

29 June 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure - Pathophysiology and Mechanisms 1 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2021

About the speaker

Photo
Professor Ewa Straburzynska-Migaj

Poznan University of Medical Sciences, Poznan (Poland)

9 More presentations in this session

Presentation thumbnail
Real world analysis of outcomes of remote pulmonary artery hemodynamic monitoring in overweight and obese patients with heart failure
Doctor M. Oberoi (Sioux Falls, US)
Abstract Slides Video
Presentation thumbnail
Multicenter nationwide study of the prevalence of ATTR-CM in HFpEF in Spain. Intermediate results from national PRACTICA study.
Doctor J. Garcia-Pinilla (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction
Mr J. Yang (South San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies
Doctor K. Jering (Boston, US)
Abstract Slides
Presentation thumbnail
Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)
Doctor J. Ezekowitz (Edmonton, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic Heart Failure - Pathophysiology and Mechanisms 1

The Event

Event poster

Heart Failure 2021

29 June - 1 July 2021
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources